Table 1.
Clinical and demographic characteristics of patients with NHL
| Variables | Controls n=40 |
Patients n=100 |
Pb | ||
|---|---|---|---|---|---|
| Exposed controls n=20 |
Not exposed controls n=20 |
Exposed patients n=32 |
Not exposed patients n=68 |
||
| Age (year) | 56.12±2.93 | 56.6±3.1 | 58.48±3.27 | 55.25±2.82 | 0.901 |
| Pa | 0.911 | 0.492 | |||
| Sex (M/F) | 12/8 | 11/9 | 18/14 | 35/33 | 0.911 |
| Pa | 0.749 | 0.817 | |||
| BMI (kg/m2) | 22.84±0.64 | 22.45±0.55 | 22.53±0.76 | 22.2±0.5 | 0.920 |
| Pa | 0.647 | 0.713 | |||
| LDH (U/L) | 208.73±57.29 | 194.42±59.74 | 498.72±75.77 | 489.24±84.61 | 0.049 |
| Pa | 0.865 | 0.944 | |||
| ALP (U/100 mL) | 87.25±13.41 | 83.57±14.13 | 136.54±16.54 | 132.71±10.47 | 0.021 |
| Pa | 0.850 | 0.841 | |||
| NLR | 1.82±0.09 | 1.76±0.06 | 2.34±0.03 | 2.16±0.06 | 0.000 |
| Pa | 0.582 | 0.000 | |||
| NHL type | – | ||||
| B-cell NHL | – | 84.38 | 86.76 | – | |
| Pa | – | 0.748 | |||
| T-cell NHL | – | 15.63 | 13.24 | – | |
| Pa | – | 0.748 | |||
| Clinical stage | – | ||||
| CS I (%) | – | 40.63 | 42.65 | – | |
| Pa | – | 0.848 | |||
| CS II (%) | – | 21.88 | 20.59 | – | |
| Pa | – | 0.883 | |||
| CS III (%) | – | 25 | 22.06 | – | |
| Pa | – | 0.744 | |||
| CS IV (%) | – | 12.5 | 14.71 | – | |
| Pa | – | 0.767 | |||
Notes: P<0.05 was considered statistically significant. Data are presented as mean ± standard error. Student’s t-test; Pa: exposed controls versus not exposed controls or exposed patients versus not exposed patients, one-way ANOVA; Pb: comparison between the four groups.
Abbreviations: ALP, alkaline phosphatase; ANOVA, analysis of variance; BMI, body mass index; CS, clinical stage; F, female; LDH, lactate dehydrogenase; M, male; NHL, non-Hodgkin lymphoma.